BRISBANE, May 03, 2019 (GLOBE NEWSWIRE via COMTEX) --
BRISBANE, Calif., May 03, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc.
, a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that AlloMap will be a contracted service with Anthem Blue Cross of California (Anthem) and 10 of its affiliated health plans to optimize the care of heart transplant recipients.
The agreements include Anthem in California and its affiliates in Connecticut, New Hampshire, Maine, Georgia, Virginia, Indiana, Ohio, Kentucky, Missouri and Wisconsin.
"Our in-network participation with Anthem and its affiliated health plans highlights the strong relationship between CareDx and national private payors," said Peter Maag, CEO of CareDx. "We are proud to make AlloMap accessible to heart transplant patients across the US with approximately 80% of all insured lives now covered for AlloMap."
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum, and is the leading provider of genomics-based information for transplant patients.
For more information, please visit: www.CareDx.com .
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts, including statements regarding Anthem. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies and other risks discussed in CareDx's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed by CareDx with the SEC on March 6, 2019 and other reports that CareDx has filed with the SEC. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Chief Commercial Officer
Integrated Corporate Relations, Inc.
(C) Copyright 2019 GlobeNewswire, Inc. All rights reserved.